Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | [225Ac]Ac-FL-261 |
| Synonyms | |
| Therapy Description |
[225Ac]Ac-FL-261 is a radionuclide drug conjugate (RDC) targeting MET, which potentially inhibits growth of Met-expressing tumors (Cancer Res (2026) 86 (7_Supplement): 5825). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| [225Ac]Ac-FL-261 | FL-261|[225Ac]-FL-261|225Ac-FL-261 | MET Antibody 42 | [225Ac]Ac-FL-261 is a radionuclide drug conjugate (RDC) targeting MET, which potentially inhibits growth of Met-expressing tumors (Cancer Res (2026) 86 (7_Supplement): 5825). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07873450 | Phase Ib/II | [225Ac]Ac-FL-261 | SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET | Recruiting | USA | AUS | 0 |